Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 4.50 and last traded at GBX 4.70, with a volume of 366805 shares changing hands. The stock had previously closed at GBX 5.
Allergy Therapeutics Stock Performance
The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The firm has a market capitalization of £297.63 million, a PE ratio of -4.85, a PEG ratio of -30.70 and a beta of 0.83. The firm’s fifty day moving average price is GBX 5.74 and its 200 day moving average price is GBX 8.31.
Allergy Therapeutics Company Profile
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Read More
- Five stocks we like better than Allergy Therapeutics
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
- Rocket Lab Insiders Are Selling—But Institutions Keep Buying
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
